Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375748 | 0.93 | ALDH1A1 (0.43) | CA12CA1CA2CA9NAAA | |
| SCHEMBL2797756 | 0.84 | HCAR2 (0.31) | HCAR2ALDH1A1 | |
| SCHEMBL9489882 | 0.74 | EPHX1 (0.53) | CA12CA1CA2CA9NAAA | |
| Guanidine SCHEMBL10879764 | 0.74 | EPHX1 (0.49) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL28481544 | 0.72 | EPHX1 (0.57) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL1456856 | 0.72 | EPHX1 (0.57) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL5583745 | 0.72 | EPHX1 (0.57) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL28518473 | 0.72 | EPHX1 (0.57) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL987628 | 0.72 | EPHX1 (0.57) | NAAAEPHX1TSHRHCAR2ALDH1A1 | |
| SCHEMBL27403281 | 0.72 | EPHX1 (0.57) | NAAAEPHX1TSHRHCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739349-B1 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 2000-05-17 | — | — | EP | claimed |
| US-5616698-A | Polymer-supported solution synthesis of oligosaccharides | UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1997-04-01 | — | — | US | claimed |
| EP-0739349-A1 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 1996-10-30 | — | — | EP | claimed |
| WO-1995018814-A2 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 1995-07-13 | — | — | WO | claimed |
| CN-113024486-A | Method for preparing oseltamivir intermediate | 上海奥博生物医药技术有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-113024489-A | Preparation method of oseltamivir synthesis process impurity | 上海奥博生物医药技术有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-7256198-B2 | Pyrimidoindolones and methods for using same | WYETH (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
| US-6121271-A | ANTIDIABETIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | TYMP, DPYD, TYMS | CA12 4865/4885CA1 4377/4885CA2 4697/4885 |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | CASP1, API5, CASP8 | CA12 4864/4885CA1 3307/4885CA2 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.